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The choice of the most appropriate systemic treatment of patients with metastatic breast carcinoma is a multifaceted
decision-making process. The role for the pathologist is to provide a definite diagnosis of metastatic breast carcinoma,
whenever needed, and especially to assess the biological parameters with prognostic and predictive value.
Although the vast majority of breast carcinomas maintain the same biological features both in the primary and in the
metastases, some undergo changes that may indicate that a targeted systemic treatment should be stopped or
started, be it endocrine or anti-HER2. Unfortunately these tumours cannot be easily identified clinically, and it may be
useful to biopsy the metastatic sites for reassessment of the biological characteristic of the tumours. Intra-tumoural
heterogeneity and clonal selection due to the therapy could explain changes in biological features during tumour
progression, but it should also be taken into account that the available assays for evaluating hormone receptor and
HER2 status are not 100% accurate, even in the hands of expert pathologists. To minimize the risk of inducing
inappropriate changes in systemic treatments due to false-positive or false-negative results, the pathologists should
make all efforts to improve accuracy and reproducibility of the assay procedures.
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introduction
The selection of the most appropriate systemic treatment of
patients with metastatic breast carcinoma is guided by
a combination of disease- and patient-related factors. These
include the hormone receptor (HR) and HER2 status of the
primary tumour or its metastases, the length of disease-free
interval since surgery and since completion of adjuvant
treatments, the effects and tolerance of previous therapies, the
number and sites of metastatic lesions, the age, menopausal
status, comorbidities and performance status of the patient,
the availability and access to treatments and patient
preference [1–3].
In this multifaceted decision-making process, the pathologist
may be required to confirm that the lesions actually are
metastases from the primary breast cancer, and to characterize
the biological features of the metastatic tumour by reassessing
HR and HER2 status.
diagnosis of metastatic breast cancer
Despite the consensus that histological or cytological
confirmation of metastatic disease is not required routinely [3],
a biopsy of the metastatic lesion may be advisable in case of
ambiguity. Fine-needle aspiration cytology (FNAC) may be
a reasonable approach for accessible metastatic sites, with
minimal morbidity for the patients. FNAC is a very accurate
diagnostic tool for metastatic disease, with a negligible
false-positive rate, and a false-negative rate strictly dependent
on the sampling procedure. Cytological preparations of
metastatic tumour are suitable for the assessment of HR status
by immunocytochemical assays, whereas HER2 status has to be
evaluated using in situ hybridization assays with either
fluorescent (FISH) or chromogenic (CISH or SISH) probes.
When carrying out FNAC for a suspected metastasis of breast
carcinoma, it is necessary to foresee the need for the biological
characterization of the neoplastic cells. This implies that the
lesion has to be extensively sampled, and multiple cytological
preparations obtained to allow for complete characterization of
the disease.
Biopsies of the suspected lesions allow better characterization
of the morphological and biological features of the tumours.
Not infrequently, a biopsy of a suspected metastasis from breast
cancer shows non-neoplastic disease, or a different tumour,
either a second primary or a metastasis from an unsuspected
non-mammary primary. Examples include suspected breast
metastases to the lung revealed to be primary lung tumours, or
liver metastases thought to originate from breast cancer, but
actually representing either metastatic neuroendocrine tumours
from the gastrointestinal tract, or metastases from tumours of
different origin. It is therefore essential that the pathologist
examining a suspected breast metastasis always thinks of the
possibility of a different tumour, especially when the neoplastic
cells exhibit a negative HR status. In this case, the
morphological features of the tumour may not be sufficient to
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out immunohistochemical assays for the identification of
markers indicating an alternative possible origin of the
metastatic disease (e.g. GCFDP-15 for the breast, TTF-1 for the
lung, CDX2 for the gastrointestinal tract, etc.).
assessment of the biological features
It is still debated whether the reassessment of the biological
features (HR and HER2 status) of metastatic breast cancer per
se justifies a biopsy of the metastatic site, whenever this is
feasible. There may be two different scenarios. In the
unlikely event that the HR and HER2 status of the primary
tumour is not known, this information undoubtedly has to be
collected, either by retrieving and examining the
original tumour samples, or by carrying out a biopsy of the
metastasis.
If the biological features of the primary tumour are known,
the question arises of whether it is worth reassessing HR and
HER2 status of the metastasis. Those who advise reassessment
of the biological features of the metastases whenever feasible
support their recommendation by emphasizing that breast
tumours have been repeatedly reported to potentially undergo
changes of their biological characteristics during tumour
progression. Indeed, several studies in the last decades have
documented changes in HR and HER2 status of some
10%–20% of the metastases as compared with the breast
primary [4–10]. As a matter of fact, however, the vast majority
of metastases maintain the biological features of the primary
tumours, and we cannot easily identify those tumours most
likely to undergo changes (and therefore worth being biopsied
at the metastatic site). Some hints that a tumour may have
changed its biological features may be derived from the clinical
course of the disease, and the response to systemic treatments.
If the time to recurrence or the site of recurrence appear to be
different from what is expected according to the features of the
primary tumour, then reassessing HR and HER2 status in
the metastasis is very important for optimal treatment choice.
The changes in the biological features of the metastatic
tumours mandate stopping or starting a targeted systemic
treatment, be it endocrine or anti-HER2. Patients who no
longer have HR-positive cancers at the time of recurrence are
unlikely to benefit from further endocrine therapy. On the
other hand, tumours that acquire estrogen receptor (ER) or
HER2 expression might become responsive to endocrine or
HER2-targeted therapies. The most commonly accepted
biological explanations for change in receptor status are
tumour heterogeneity with a possible clonal selection due to
therapy, and divergent differentiation of breast tumorigenic
cells during the course of the disease [11]. Discordance for ER,
progesterone receptor and HER2 was encountered in 18.4%,
40.3% and 13.6%, respectively, of 789 patients with recurrent
breast cancer in a recent study [12]. Patients with concordant
receptor-positive breast cancer had significantly better post-
recurrence survival than discordant cases; patients with
discordant receptor status had an unfavourable survival as did
patients with concordant triple-negative disease. The poor
survival of patients with tumours exhibiting changes in
receptor status was probably due to inappropriate use of
targeted therapies.
The importance of an accurate assessment of the predictive
parameter cannot be overemphasized. Unfortunately, however,
we have to admit that the currently available assays
(immunohistochemistry and in situ hybridization) are not
100% accurate and reproducible, even in the hands of
experienced pathologists. Therefore, when using an assay that
has a 5% error rate (implying that it has a remarkable accuracy
of 95%) to test the primary tumour and thereafter the
metastatic tumour, the risk of a different assessment of the
biological parameter under study is 10%. If the error rate of
the assay is higher, then the risk of apparent changes in the
biological features of the tumours increases dramatically, and it
becomes almost impossible to ascertain whether the tumour
has actually changed during progression or if the changes
reflect the imperfect accuracy of the testing procedures. The
diagnostic problem is that considering the two separate test
results alone, one cannot determine whether the first or second
biopsy result was correct for these discordant cases.
To try and minimize the possibility of a false assessment of
changes in the biology of the tumour, and hence in the expected
response to the therapeutic approaches, the pathologist has to
double-check the reliability of the results before reporting any
change in the HR and HER2 status of the metastatic tumours. To
do this, it is advisable to repeat the assays for the biological
variables that are discordant in the primary and metastatic
samples on both lesions simultaneously in the same testing
conditions. This will reduce the chance of errors due to the
analytical procedures. Another useful suggestion would be to add
a confirmatory test (e.g. a FISH assay for HER2 in the case of
discordant immunohistochemical results or vice versa) before
rendering the final diagnosis. Though this policy will not
completely eliminate false-positive and false-negative results, in
the experience of the authors it has been proved to remarkably
reduce the ER and HER2 discordance rate between primary and
recurrent tumours. If this may avoid an inappropriate change in
systemic treatment of some patients it is well worth the
additional effort and costs afforded by the pathologists.
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